BRAF and neoplasm: BRAFi (vemurafenib), MEKi (selumetinib) or ERKi (SCH772984) combined to kill BRAF-mutant A375 and WM266-4 cells in a caspase-dependent fashion (Fig. 2i) but only selumetinib or SCH772984 were effective in NRASQ61K-mutant SK-MEL-30 cells, consistent with vemurafenib efficacy being confined to BRAF-mutant tumour cells.